Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

Also called NCT05573477

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Autotelicbio (from the registry)
Registry
  • NCT NCT05573477
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05573477. Randomized; double masking; primary purpose treatment. Start 2022-11-16 (actual); primary completion 2025-08-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
Condition
Essential Hypertension
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
ATB-1011
Intervention (Drug)
ATB-1012
Intervention (Drug)
ATB-1013
Intervention (Drug)
ATB-1011 placebo
Intervention (Drug)
ATB-1012 placebo
Intervention (Drug)
ATB-1013 placebo
Lead sponsor
Autotelicbio (class: industry)

Record details

Record id
cardio:ct-nct05573477
Content hash
babc69fbe7a51e1ee2bcf7f0fea46ea90a27f5c1b69bf8fbe89cfd5696fed590